ReviewJPRAS open2023
Botulinum Toxin A for Hair Loss Treatment: A Systematic Review of Efficacy, Safety, and Future Directions.
Review in JPRAS open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.
- Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia-A Systematic Review with Network Meta-Analyses.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Review
- Botulinum Toxin Vascular Effectiveness: Low or High Doses?Aesthetic plastic surgery · 2026Review
- The Effects of Botulinum Toxin on Vascular Diameter: A Preliminary Report.Journal of cosmetic dermatology · 2025Article
- Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.Drug design, development and therapy · 2025Review
- Frontal Fibrosing Alopecia: A Comprehensive Guide for Cosmetic Dermatologists.Dermatology and therapy · 2025Review
- Evaluation of the safety and efficacy of concentrated growth factors for hair growth promotion in androgenetic alopecia patients: A retrospective single-centre, single-arm study.Journal of cosmetic dermatology · 2024Article
- Efficacy and safety of botulinum toxin A in the treatment of female pattern hair loss.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hair loss is a common condition with significant impact globally, yet its treatment efficacy and safety remain debated. Botulinum toxin A (BoNT-A) has emerged as a potential therapeutic option, but a comprehensive review on this topic is lacking Objective: This review critically evaluates the current evidence on BoNT-A for hair loss treatment, highlighting the gaps in previous reviews and providing a comprehensive analysis of its efficacy, safety, and future prospects. Methods: A systematic search of electronic databases identified relevant studies published up to September 2022 Results: Prior reviews primarily focused on androgenetic alopecia and lacked the evaluation of other alopecia types and underlying mechanisms. Our review addresses this gap, incorporating a broader spectrum of hair loss conditions. Mechanisms of BoNT-A in hair growth modulation, potential side effects, and future research directions are discussed. Conclusion: This review adds to the existing body of knowledge by providing a comprehensive evaluation of BoNT-A in hair loss treatment. The findings will serve as a foundation for further research and guide clinicians in making informed decisions, ultimately improving the outcomes and quality of life for individuals suffering from hair loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.